July 19, 2024
Read the latest article from HealthTree Foundation covering EasyM™, our novel, ultra sensitive blood-based clonotypic peptides mass spectrometry assay for the monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM).
In this article, learn about how MRD is monitored with current and up-and-coming technologies. Discover the benefits of an ultrasensitive mass spectrometry multiple myeloma blood test, EasyM, and how it can improve the monitoring of minimal residual disease in MM patients.
About HealthTree Foundation
HealthTree Foundation is a global nonprofit organization dedicated to improving outcomes and finding cures for blood cancers through cutting-edge technology, patient education, and research collaboration. The foundation’s HealthTree Cure Hub® Registry provides a powerful patient data portal where over 10,000 patients contribute real-world data, enabling researchers to drive lifesaving discoveries. By uniting patients and researchers, HealthTree is revolutionizing cancer care and accelerating cures. For more information, visit healthtree.org.
